Interplay of Dinner Timing and MTNR1B Type 2 Diabetes Risk Variant on Glucose Tolerance and Insulin Secretion: A Randomized Crossover Trial.

Marta Garaulet, Jesus Lopez-Minguez, Hassan S Dashti, Céline Vetter, Antonio Miguel Hernández-Martínez, Millán Pérez-Ayala, Juan Carlos Baraza, Wei Wang, Jose C Florez, Frank A J L Scheer, Richa Saxena

Journal: Diabetes care 2022;45(3):512-519

PMID: 35015083

Abstract

OBJECTIVE

We tested whether the concurrence of food intake and elevated concentrations of endogenous melatonin, as occurs with late eating, results in impaired glucose control, in particular in carriers of the type 2 diabetes-associated G allele in the melatonin receptor-1B gene (MTNR1B).

RESEARCH DESIGN AND METHODS

In a Spanish natural late-eating population, a randomized, crossover study was performed. Each participant (n = 845) underwent two evening 2-h 75-g oral glucose tolerance tests following an 8-h fast: an early condition scheduled 4 h prior to habitual bedtime ("early dinner timing") and a late condition scheduled 1 h prior to habitual bedtime ("late dinner timing"), simulating an early and a late dinner timing, respectively. Differences in postprandial glucose and insulin responses between early and late dinner timing were determined using incremental area under the curve (AUC) calculated by the trapezoidal method.

RESULTS

Melatonin serum levels were 3.5-fold higher in the late versus early condition, with late dinner timing resulting in 6.7% lower insulin AUC and 8.3% higher glucose AUC. The effect of late eating impairing glucose tolerance was stronger in the MTNR1B G-allele carriers than in noncarriers. Genotype differences in glucose tolerance were attributed to reductions in β-cell function (P for interaction, Pint glucose area under the curve = 0.009, Pint corrected insulin response = 0.022, and Pint disposition index = 0.018).

CONCLUSIONS

Concurrently high endogenous melatonin and carbohydrate intake, as typical for late eating, impairs glucose tolerance, especially in MTNR1B G-risk allele carriers, attributable to insulin secretion defects.

© 2022 by the American Diabetes Association.

Address: Department of Physiology, University of Murcia, Murcia, Spain.; Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca, Murcia, Spain.; Division of Sleep and Circadian Disorders, Brigham and Women's Hospital, Boston, MA.; Center for Genomic Medicine, Massachusetts General Hospital, Boston, MA.; Broad Institute, Cambridge, MA.; Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA.; Department of Integrative Physiology, University of Colorado Boulder, Boulder, CO.; Department of Endocrinology and Nutrition, "Virgen Arrixaca" Hospital and University of Murcia, Murcia, Spain.; Department of Clinical Analysis, Virgen de la Arrixaca University Hospital, Murcia, Spain.; Division of Sleep Medicine, Harvard Medical School, Boston, MA.; Department of Medicine, Harvard Medical School, Boston, MA.
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.